Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

VVERTEX PHARMACEUTICALS INC

EconomyAI buildoutMarket MapFundsWatchlist
Log in
V

VERTEX PHARMACEUTICALS INC

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • Insider Transactions
Loading financials
Income statement income statement flow. Revenue $3.33B. Net result $1.1B.

Income statement revenue $3.33B (+12.5% YoY).Operating income $1.25B (+8.3% YoY).Pre-tax result $1.39B (+8.5% YoY).Net result $1.1B (+6.5% YoY).

  • ALYFTREK: $573.6M (+265.8% YoY)
  • CASGEVY: $76.4M (+151.3% YoY)
  • JOURNAVX: $49.6M (+313.3% YoY)
  • Manufactured Product Other: $137.1M (-29.2% YoY)
  • TRIKAFTAKAFTRIO: $2.5B (-2.1% YoY)
  • Research and development expenses: $993.8M (+1.6% YoY)
  • Acquired in-process research and development expenses: $21.4M (+872.7% YoY)
  • Selling, general and administrative expenses: $582.2M (+37.1% YoY)
  • Change in fair value of contingent consideration: $400K (-55.6% YoY)
  • Other income: $144.9M (+9.9% YoY)
  • Income tax expense: $292M (+16.8% YoY)